Storia in 3 fonti

Deals, deals, deals; Biohaven takes on Eli Lilly; and more

Welcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan writes that US biotech companies are holding ...

Raccontata da

fiercepharma.com

statnews.com

endpoints.news

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Deals, deals, deals; Biohaven takes on Eli Lilly; and more

Welcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan writes that US biotech companies are holding ...

originale

fiercepharma.com1 mese fa

A $10B deal, China trial scrutiny and highlights from ADA 2026

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. | This week on "The Top Line," we’re covering…

Leggi questa versione → originale

Timeline cronologica

venerdì 10 luglio 2026·fiercepharma.com
A $10B deal, China trial scrutiny and highlights from ADA 2026
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. | This…
venerdì 10 luglio 2026·statnews.com
Roche ends Huntington's gene-silencing programs
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout

Deals, deals, deals; Biohaven takes on Eli Lilly; and more

A $10B deal, China trial scrutiny and highlights from ADA 2026

Timeline cronologica

A $10B deal, China trial scrutiny and highlights from ADA 2026

Roche ends Huntington's gene-silencing programs

Roche ends Huntington's gene-silencing programs

'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive

Deals, deals, deals; Biohaven takes on Eli Lilly; and more